Zhiyi Biotech, a leading company in Live Biotherapeutics products and next-generation
probiotics, will accelerate the clinical development of its new drugs with the
Zhiyi Biotech (Chinese: 知易生物) completed a Series B++
financing round worth CNY 100 million (USD 14.92 million) recently. This round
was jointly invested by SDIC Venture Capital (Chinese: 国投创业), GDD Fund (Chinese: 广州开发区基金) and Helichuangxing Group (Chinese:
合利创兴集团).
The funding will be used to accelerate the
clinical development of its new drug pipelines. Zhiyi Biotech has raised CNY 300
million (USD 44.79 million) in the past 18 months.
Founded in 2013, Zhiyi Biotech, focusing on new drug research
& development and is a leading company in Live Biotherapeutics products (LBPs)
and next-generation probiotics in China. The company has established a complete
technical system for the spectra of microorganisms and pathogenic bacteria, the
isolation and target identification of new functional strains as well as the
development of new live biotherapeutics and active ingredients. Zhiyi also has
a complete industrialization platform from preclinical to NDA.
Zhiyi's competitors include Akesobio (Chinese:
康方生物), WuXi
Biologics (Chinese: 药明生物) and RemeGen (Chinese: 荣昌生物).